13th Jan 2022 12:06
(Alliance News) - Angle PLC said on Thursday it has begun the accreditation process for its UK and US laboratories, as delays push back its ovarian cancer study.
The Surrey, England-based liquid biopsy company said first submissions have now been made to Clinical Laboratory Improvement Amendments, a US regulator, and UK Accreditation Service, the UK regulator, in relation to its US and UK laboratories. The US accreditation process is pending the results of Angle's blood test for ovarian cancer technology.
Angle's ovarian cancer study has been delayed by "unexpected" third-party supply chain problems due to Covid-19, with critical lipids unable to be delivered. Results are now expected in the first half of 2022.
Angle founder and Chief Executive Andrew Newland commented: "We remain on track to achieve the first ever US Food & Drug Administration product clearance, the gold standard for medical devices globally, for a system to harvest cancer cells from patient blood for subsequent analysis, initially in metastatic breast cancer. Ongoing and constructive dialogue with FDA continues and a regulatory decision from FDA is awaited."
Angle's share price rose by 1.4% to 122.70 pence each in London during Thursday midday trading.
By Elizabeth Winter; [email protected]
Copyright 2022 Alliance News Limited. All Rights Reserved.
Related Shares:
Angle